MACROPHAGE MIGRATION INHIBITORY FACTOR LEVELS CORRELATE WITH FATAL OUTCOME IN SEPSIS

Macrophage migration inhibitory factor (MIF) is a cytokine playing a critical role in the pathophysiology of experimental sepsis. The purpose of this study was to determine the levels of MIF and to compare those to interleukin-6 (IL-6) levels in predicting mortality among critically ill patients with sepsis. The levels of MIF and IL-6 were measured in 25 patients with septic shock, 17 patients with sepsis, and 11 healthy volunteers. The median plasma concentrations of MIF and IL-6 were significantly higher in patients with septic shock and in patients with sepsis than in healthy controls. MIF levels were significantly different between survivors and nonsurvivors, as were IL-6 levels. Discriminatory power in predicting mortality, as assessed by the areas under receiver operating characteristic curves (AUROC), was 0.793 for MIF and 0.680 for IL-6. Finally, high plasma levels of MIF (>1100 pg/mL) had a sensitivity of 100% and a specificity of 64% to identify the patients who eventually would evolve to a fatal outcome. Thus, our data suggest that an elevated MIF level in recently diagnosed septic patients appears to be an early indicator of poor outcome and a potential entry criterion for future studies with therapeutic intervention aiming at MIF neutralization.

[1]  R. Bucala,et al.  Macrophage migration inhibitory factor. , 2005, Critical care medicine.

[2]  C. Coopersmith,et al.  Antibiotics Improve Survival in Sepsis Independent of Injury Severity but do not Change Mortality in Mice with Markedly Elevated Interleukin 6 Levels , 2004, Shock.

[3]  F. Bozza,et al.  Antibiotic treatment in a murine model of sepsis: impact on cytokines and endotoxin release. , 2004, Shock.

[4]  R. Exner,et al.  Continuous Therapeutic Epinephrine but not Norepinephrine Prolongs Splanchnic IL-6 Production in Porcine Endotoxic Shock , 2003, Shock.

[5]  S. Opal.  Clinical Trial Design and Outcomes in Patients with Severe Sepsis , 2003, Shock.

[6]  Peter A. Ward,et al.  Novel strategies for the treatment of sepsis , 2003, Nature Medicine.

[7]  R. Bucala,et al.  Role for macrophage migration inhibitory factor in acute respiratory distress syndrome , 2003, The Journal of pathology.

[8]  Charles Natanson,et al.  Risk and the efficacy of antiinflammatory agents: retrospective and confirmatory studies of sepsis. , 2002, American journal of respiratory and critical care medicine.

[9]  V. Pettilä,et al.  Predictive value of procalcitonin and interleukin 6 in critically ill patients with suspected sepsis , 2002, Intensive Care Medicine.

[10]  J. Siddiqui,et al.  Six at Six: Interleukin-6 Measured 6 H After the Initiation of Sepsis Predicts Mortality Over 3 Days , 2002, Shock.

[11]  J. Vincent,et al.  Clinical trials of immunomodulatory therapies in severe sepsis and septic shock. , 2002, Clinical infectious diseases : an official publication of the Infectious Diseases Society of America.

[12]  J. Bernhagen,et al.  Macrophage migration inhibitory factor (MIF): mechanisms of action and role in disease. , 2002, Microbes and infection.

[13]  T. Calandra,et al.  MIF regulates innate immune responses through modulation of Toll-like receptor 4 , 2001, Nature.

[14]  I. Chaudry,et al.  Norepinephrine-induced hepatocellular dysfunction in early sepsis is mediated by activation of alpha2-adrenoceptors. , 2001, American journal of physiology. Gastrointestinal and liver physiology.

[15]  A. Hoeft,et al.  Plasma levels of macrophage migration inhibitory factor are elevated in patients with severe sepsis , 2001, Intensive Care Medicine.

[16]  O. Kemmotsu,et al.  Macrophage migration inhibitory factor is a critical mediator of systemic inflammatory response syndrome , 2001, Intensive Care Medicine.

[17]  L. Thijs,et al.  Macrophage migration inhibitory factor and hypothalamo-pituitary-adrenal function during critical illness. , 2001, The Journal of clinical endocrinology and metabolism.

[18]  R. Bucala,et al.  Protection from septic shock by neutralization of macrophage migration inhibitory factor , 2000, Nature Medicine.

[19]  K. Tracey,et al.  HMG-1 as a late mediator of endotoxin lethality in mice. , 1999, Science.

[20]  A. Satoskar,et al.  Targeted Disruption of Migration Inhibitory Factor Gene Reveals Its Critical Role in Sepsis , 1999, The Journal of experimental medicine.

[21]  R. Bucala,et al.  Macrophage migration inhibitory factor is a critical mediator of the activation of immune cells by exotoxins of Gram-positive bacteria. , 1998, Proceedings of the National Academy of Sciences of the United States of America.

[22]  H. Makita,et al.  Effect of anti-macrophage migration inhibitory factor antibody on lipopolysaccharide-induced pulmonary neutrophil accumulation. , 1998, American journal of respiratory and critical care medicine.

[23]  R. Bucala,et al.  Regulatory role for macrophage migration inhibitory factor in acute respiratory distress syndrome , 1997, Nature Medicine.

[24]  R. Bucala,et al.  An essential regulatory role for macrophage migration inhibitory factor in T-cell activation. , 1996, Proceedings of the National Academy of Sciences of the United States of America.

[25]  J. Bernhagen,et al.  MIF as a glucocorticoid-induced modulator of cytokine production , 1995, Nature.

[26]  J. Sjölin,et al.  Plasma levels of cytokines in primary septic shock in humans: correlation with disease severity. , 1995, The Journal of infectious diseases.

[27]  J. Bernhagen,et al.  Purification, bioactivity, and secondary structure analysis of mouse and human macrophage migration inhibitory factor (MIF). , 1994, Biochemistry.

[28]  J. Bernhagen,et al.  The macrophage is an important and previously unrecognized source of macrophage migration inhibitory factor , 1994, The Journal of experimental medicine.

[29]  K. Tracey,et al.  MIF is a pituitary-derived cytokine that potentiates lethal endotoxaemia , 1993, Nature.

[30]  R. Bone,et al.  Plasma Cytokine and Endotoxin Levels Correlate with Survival in Patients with the Sepsis Syndrome , 1993, Annals of Internal Medicine.

[31]  C. Stewart,et al.  Mechanistic differences between migration inhibitory factor (MIF) and IFN-gamma for macrophage activation. MIF and IFN-gamma synergize with lipid A to mediate migration inhibition but only IFN-gamma induces production of TNF-alpha and nitric oxide. , 1993, Journal of immunology.

[32]  W. Knaus,et al.  Definitions for sepsis and organ failure and guidelines for the use of innovative therapies in sepsis. The ACCP/SCCM Consensus Conference Committee. American College of Chest Physicians/Society of Critical Care Medicine. , 1992, Chest.

[33]  P Franchimont,et al.  Cytokine serum level during severe sepsis in human IL-6 as a marker of severity. , 1992, Annals of surgery.

[34]  T. Calandra,et al.  High circulating levels of interleukin-6 in patients with septic shock: evolution during sepsis, prognostic value, and interplay with other cytokines. The Swiss-Dutch J5 Immunoglobulin Study Group. , 1991, The American journal of medicine.

[35]  E. Draper,et al.  APACHE II: A severity of disease classification system , 1985, Critical care medicine.

[36]  J. David.  Delayed hypersensitivity in vitro: its mediation by cell-free substances formed by lymphoid cell-antigen interaction. , 1966, Proceedings of the National Academy of Sciences of the United States of America.

[37]  B. Bloom,et al.  Mechanism of a Reaction in Vitro Associated with Delayed-Type Hypersensitivity , 1966, Science.

[38]  G. V. Poole,et al.  Trauma patients with positive cultures have higher levels of circulating macrophage migration inhibitory factor (MIF). , 2000, Research communications in molecular pathology and pharmacology.

[39]  R. Atkins,et al.  Migration inhibitory factor expression in experimentally induced endotoxemia. , 1997, The American journal of pathology.